Functional heterogeneity within tumors presents a significant therapeutic challenge. Here we show that quiescent, therapy-resistant Sox2+ cells propagate sonic hedgehog subgroup medulloblastoma by a mechanism that mirrors a neurogenic program. Rare Sox2+ cells produce rapidly cycling doublecortin+ progenitors that, together with their postmitotic progeny expressing NeuN, comprise tumor bulk. Sox2+ cells are enriched following anti-mitotic chemotherapy and Smoothened inhibition, creating a reservoir for tumor regrowth. Lineage traces from Sox2+ cells increase following treatment, suggesting that this population is responsible for relapse. Targeting Sox2+ cells with the antineoplastic mithramycin abrogated tumor growth. Addressing functional ...
SummaryMedulloblastoma is the most common malignant brain tumor in children, but the cells from whic...
Medulloblastoma is one of the most frequent and aggressive tumors of childhood. The Sonic hedgehog (...
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and sho...
SummaryFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we ...
SummaryFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we ...
Single cancers can be comprised of highly heterogeneous cell populations. In brain tumours, includin...
Single cancers can be comprised of highly heterogeneous cell populations. In brain tumours, includin...
Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express s...
Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express s...
Medulloblastoma is the most common malignant brain tumor in children. Although aggressive surgery, r...
Medulloblastoma is the most common malignant pediatric brain tumour. Current therapies fail to provi...
Medulloblastomas and glioblastomas are devastating tumors that respond poorly to treatment. These tu...
<div><p>Medulloblastomas and glioblastomas are devastating tumors that respond poorly to treatment. ...
AbstractMedulloblastoma is the most common malignant pediatric brain tumor. Current treatment is ass...
Medulloblastoma is the most common malignant brain tumor in children, but the cells from which it ar...
SummaryMedulloblastoma is the most common malignant brain tumor in children, but the cells from whic...
Medulloblastoma is one of the most frequent and aggressive tumors of childhood. The Sonic hedgehog (...
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and sho...
SummaryFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we ...
SummaryFunctional heterogeneity within tumors presents a significant therapeutic challenge. Here we ...
Single cancers can be comprised of highly heterogeneous cell populations. In brain tumours, includin...
Single cancers can be comprised of highly heterogeneous cell populations. In brain tumours, includin...
Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express s...
Glioblastoma, the most aggressive cerebral tumor, is invariably lethal. Glioblastoma cells express s...
Medulloblastoma is the most common malignant brain tumor in children. Although aggressive surgery, r...
Medulloblastoma is the most common malignant pediatric brain tumour. Current therapies fail to provi...
Medulloblastomas and glioblastomas are devastating tumors that respond poorly to treatment. These tu...
<div><p>Medulloblastomas and glioblastomas are devastating tumors that respond poorly to treatment. ...
AbstractMedulloblastoma is the most common malignant pediatric brain tumor. Current treatment is ass...
Medulloblastoma is the most common malignant brain tumor in children, but the cells from which it ar...
SummaryMedulloblastoma is the most common malignant brain tumor in children, but the cells from whic...
Medulloblastoma is one of the most frequent and aggressive tumors of childhood. The Sonic hedgehog (...
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and sho...